


## For the last five years (2018-2022)

## Cumulative achievements (2012-)

### Number of clinical trials per year



### Number of feasibility studies

Type	2018	2019	2020	2021	2022
Clinical trial availability	13	11	11	7	15
Patient survey in clinical setting	3	2	0	2	1
Resurvey of ongoing clinical trial	2	2	1	1	0
Patient referral	0	1	0	1	1
<b>Total</b>	<b>18</b>	<b>16</b>	<b>12</b>	<b>11</b>	<b>17</b>

### Number of responses to feasibility study

	2018	2019	2020	2021	2022
Subject institutions	487	503	368	476	713
Responses	436	462	346	454	691
<b>Response rates</b>	<b>89.9%</b>	<b>91.8%</b>	<b>94.0%</b>	<b>95.4%</b>	<b>96.9%</b>

### Number of clinical trials

**Total 103 trials**

- ✓ In progress : 46trials
- ✓ Completed : 53trials
- ✓ Development discontinued : 4trials

### Examples of target indications


- Pulmonary arterial hypertension
- Pediatric neurogenic detrusor overactivity
- Hemophilia
- Retinopathy of prematurity
- Short stature due to growth hormone deficiency
- Heart failure
- Status epilepticus
- Spinal Muscular Atrophy
- Ulcerative colitis
- Glioma
- Thromboprophylaxis after Fontan surgery
- Reflux esophagitis, ulcer prophylaxis with NSAIDs
- Mucopolysaccharidosis type II
- Suppression of chronic lung disease in premature infants
- Juvenile idiopathic arthritis
- Hyperuricemia
- Diabetes mellitus
- Constipation
- Hepatic encephalopathy
- Severe asthma
- Atopic dermatitis
- Hypercholesterolemia
- Hypertension
- etc...

### Number of approved medicines/devices

**Total 27 products**

Approval Status	Trade name (Target indication)
Approved in 2016	Hemangioli (Infantile hemangioma), Autologous Cultured Epidermis; JACE (Giant congenital melanocytic nevi)
Approved in 2017	Intuniv (Attention deficit hyperactivity disorder), Revatio (Pulmonary arterial hypertension), NORDITROPIN (Short stature due to Noonan syndrome)
Approved in 2018	Nexium (Gastrointestinal Diseases), IBULIEF (Patent ductus arteriosus), ORENCIA (Juvenile idiopathic arthritis), ILARIS (Systemic juvenile idiopathic arthritis), Refixia (Hemophilia B), LORA-PITA (Status epilepticus), HEMLIBRA (Hemophilia A), Precedex (Pediatric subjects in the intensive care unit)
Approved in 2019	Fiasp (Type 1 diabetes), Esperoct (Hemophilia A), LUCENTIS (Retinopathy of prematurity)
Approved in 2020	BUCCOLAM (Epilepsy), Xarelto (Thrombosis), IZCARGO (Mucopolysaccharidosis type II)
Approved in 2021	EVRYSDI (Spinal Muscular Atrophy), AZILVA (Hypertension), FENTOS Tapes (Cancer pain), Ngenla (Growth hormone deficiency short stature)
Approved in 2022	CUBICIN (MRSA infection), Toviiaz (Pediatric neurogenic detrusor overactivity), EYLEA (Retinopathy of prematurity), Precedex (Sedation during MRI)

### Trials by clinical department



### <The others>

Infectious disease / Psychiatry / Intensive care unit / Neonatology  
Plastic surgery / Genetic medicine / Neuro-oncology / Anesthesiology etc...